Analyst Activity – Canaccord Genuity Initiates Coverage On BTAI – BioXcel Therapeutics (NASDAQ:BTAI) With a Buy

Analyst Ratings For BTAI – BioXcel Therapeutics (NASDAQ:BTAI)

Story continues below

Today, Canaccord Genuity initiated coverage on BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a Buy with a price target of $21.00.

Some recent analyst ratings include

  • 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
  • 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
  • 4/2/2018-Barclays initiated coverage with a Overweight rating.


    Recent Trading Activity for BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
    Shares of BTAI – BioXcel Therapeutics closed the previous trading session at with 10.5 shares trading hands.

    An ad to help with our costs